TABLE 2.

Summary of various agents in research development to target LCSCs pathways.

Target	Agent	Population	Results	References
Wnt/β-catenin	Salinomycin	Human HCC cell lines	Reduces the tumorigenicity of LCSCs	Liu et al., 2020
Wnt	IC-2	Human HCC cell lines	Suppresses liver CSC properties	Seto et al., 2017
Hedgehog	GDC-0449	Mouse hepatoma ML-1 cells	Mitigate the mice HCC growth	Jeng et al., 2015
Hedgehog	LDE225	Human HCC cell lines	Suppress EMT and migration of metastatic cells	Ding et al., 2017
Notch	RO4929097	Miouse liver progenitor cell	Reduces Tumor Growth, Tumor Malignancy and Liver Fibrosis in vivo	Jung et al., 2016
Notch	DAPT	Human HCC cell lines	Significantly reduced CD133/epcam positivity	Kahraman et al., 2019
TGF-β	LY2157299 (Galunisertib)	Human HCC cell lines	Suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression	Rani et al., 2018
BMI1	RU-A1	Human HCC cell lines	Impair Self-Renewal and Tumorigenic Capability in HCC	Bartucci et al., 2017
NF-κB	Curcumin	Primary HCC cell line	Restrains stemness features in liver cancer	Marquardt et al., 2015
CD13	BC-02	Human HCC cell lines	Targeting CD13 and up-regulating intracellular ROS and DNA damage induced by ROS	Dou et al., 2017